Cost-effectiveness of age-related macular degeneration study supplements in the UK : combined trial and real-world outcomes data
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted..
AIMS: To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular degeneration AMD (nAMD), AREDS category 4.
METHODS: A patient-level health state transition model based on levels of visual acuity in the better-seeing eye was constructed to simulate the costs and consequences of patients taking AREDS vitamin supplements.
SETTING: UK National Health Service (NHS). The model was populated with data from AREDS and real-world outcomes and resource use from a prospective multicentre national nAMD database study containing 92 976 ranibizumab treatment episodes.
INTERVENTIONS: Two treatment approaches were compared: immediate intervention with AREDS supplements or no supplements.
MAIN OUTCOME MEASURES: quality-adjusted life years (QALYs) and healthcare costs were accrued for each strategy, and incremental costs and QALYs were calculated for the lifetime of the patient. One-way and probabilistic sensitivity analyses were employed to test the uncertainty of the model.
RESULTS: For AREDS category 3, the incremental cost-effectiveness ratio was £30 197. For AREDS category 4 compared with no intervention, AREDS supplements are more effective (10.59 vs 10.43 QALYs) and less costly (£52 074 vs 54 900) over the lifetime of the patient.
CONCLUSIONS: The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
The British journal of ophthalmology - 102(2018), 4 vom: 01. Apr., Seite 465-472 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Aaron Y [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.01.2019 Date Revised 01.04.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bjophthalmol-2017-310939 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27508292X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27508292X | ||
| 003 | DE-627 | ||
| 005 | 20231225004858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjophthalmol-2017-310939 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0916.xml |
| 035 | |a (DE-627)NLM27508292X | ||
| 035 | |a (NLM)28835423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Aaron Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of age-related macular degeneration study supplements in the UK |b combined trial and real-world outcomes data |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.01.2019 | ||
| 500 | |a Date Revised 01.04.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. | ||
| 520 | |a AIMS: To evaluate the cost-effectiveness of Age-Related Eye Disease Study (AREDS) 1 & 2 supplements in patients with either bilateral intermediate age-related macular degeneration, AREDS category 3, or unilateral neovascular age-related macular degeneration AMD (nAMD), AREDS category 4 | ||
| 520 | |a METHODS: A patient-level health state transition model based on levels of visual acuity in the better-seeing eye was constructed to simulate the costs and consequences of patients taking AREDS vitamin supplements | ||
| 520 | |a SETTING: UK National Health Service (NHS). The model was populated with data from AREDS and real-world outcomes and resource use from a prospective multicentre national nAMD database study containing 92 976 ranibizumab treatment episodes | ||
| 520 | |a INTERVENTIONS: Two treatment approaches were compared: immediate intervention with AREDS supplements or no supplements | ||
| 520 | |a MAIN OUTCOME MEASURES: quality-adjusted life years (QALYs) and healthcare costs were accrued for each strategy, and incremental costs and QALYs were calculated for the lifetime of the patient. One-way and probabilistic sensitivity analyses were employed to test the uncertainty of the model | ||
| 520 | |a RESULTS: For AREDS category 3, the incremental cost-effectiveness ratio was £30 197. For AREDS category 4 compared with no intervention, AREDS supplements are more effective (10.59 vs 10.43 QALYs) and less costly (£52 074 vs 54 900) over the lifetime of the patient | ||
| 520 | |a CONCLUSIONS: The recommendation to publicly fund AREDS supplements to category 3 patients would depend on the healthcare system willingness to pay. In contrast, initiating AREDS supplements in AREDS category 4 patients is both cost saving and more effective than no supplement use and should therefore be considered in public health policy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a age-related macular degeneration | |
| 650 | 4 | |a cost-effectiveness | |
| 650 | 4 | |a health economics | |
| 650 | 4 | |a supplements | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Zinc |2 NLM | |
| 650 | 7 | |a J41CSQ7QDS |2 NLM | |
| 700 | 1 | |a Butt, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Chew, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Agron, Elvira |e verfasserin |4 aut | |
| 700 | 1 | |a Clemons, Traci E |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Cecilia S |e verfasserin |4 aut | |
| 700 | 1 | |a Tufail, Adnan |e verfasserin |4 aut | |
| 700 | 0 | |a UK EMR AMD Research Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of ophthalmology |d 1917 |g 102(2018), 4 vom: 01. Apr., Seite 465-472 |w (DE-627)NLM000087556 |x 1468-2079 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2018 |g number:4 |g day:01 |g month:04 |g pages:465-472 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bjophthalmol-2017-310939 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2018 |e 4 |b 01 |c 04 |h 465-472 | ||